Clinical Trial Update: An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216). [Phase 3]

View source ↗

Summary

An open-label Phase 3 trial evaluating TMC125 (rilpivirine) in HIV-1 patients virologically failing DUET trials, with results posted after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC125 (rilpivirine) (rilpivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV-1 | Phase 3 | Status: COMPLETED | Results posted: 2013-03-07